Dr. Reddy's Laboratories (NSE:DRREDDY) reported a sharp Q1 profit drop to Rs 434.8 crore amid weak oncology sales, semaglutide supply halts and margin pressure from related provisions, while U.S. tariff threats could force price hikes though the company won’t shift production to the U.S.
Previous Week Recap
- Dr Reddy's Revenue, Profit Decline: DRREDDY Q1 (ended Jun 30, 2026): consolidated revenue Rs 8,099.8 crore; net profit Rs 434.8 crore, down 68.7% YoY. Company cited weak sales of a key generic oncology drug and U.S. pricing pressure.
- Semaglutide Supply Disruptions Warned: DRREDDY posted a quarterly profit miss and warned semaglutide supply disruptions: generic product unavailable in India and production halted in India and Canada until at least late October.
- Trump Tariff Plan Hit DRREDDY: Trump's U.S. tariff plan: zero tariffs on generics through July 31, 2028; 100% duties from Aug 1, 2028; 200% from Aug 1, 2029 — potential major cost impact for DRREDDY exporters.
- CEO Says No US Production Move: Dr. Reddy’s CEO Erez Israeli says the company won’t move generic drug production to the U.S.; may raise U.S. prices if tariffs hit and will await official rules before acting.
- Product Launches, ANDA/NDA Filed: Dr. Reddy's (DRREDDY) launched six North American and 43 Emerging Markets products, filed five ANDAs and one NDA, and cited near-term margin pressure from a semaglutide provision and West Asia costs.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.